NCT05493969View on ClinicalTrials.gov

Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

June 30, 2026

Conditions

Acquired Immunodeficiency Syndrome

Interventions

DRUG

Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)

Subjects will discontinue their TDF + 3TC/FTC-based regimen and will switch to DTG+3TC or fixed dose combination DTG/3TC.

All Listed Sponsors

lead

Shanghai Public Health Clinical Center

OTHER_GOV

NCT05493969 - Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity | Biotech Hunter | Biotech Hunter